DISRUPTION OF THE PROSTAGLANDIN E SYNTHASE 2 GENE

Details for Australian Patent Application No. 2002365312 (hide)

Owner PFIZER PRODUCTS INC.

Inventors FRANCONE, Omar, Luis; HAGHPASSAND, Mehrdad; AUDOLY, Laurent, Pascal; HAMBOR, John, Edward; ROACH, Marsha, Lynn; STOCK, Jeffrey, Lynn

Pub. Number AU-A-2002365312

PCT Number PCT/IB02/04693

PCT Pub. Number WO2003/045136

Priority 60/337,431 30.11.01 US; 60/405,652 22.08.02 US

Filing date 8 November 2002

Wipo publication date 10 June 2003

International Classifications

A01K 067/027 Rearing or breeding animals, not otherwise provided for - New breeds of vertebrates

C12N 005/06 Undifferentiated human, animal or plant cells, e.g. cell lines -

C12N 005/10 Undifferentiated human, animal or plant cells, e.g. cell lines - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Event Publications

14 August 2003 Complete Application Filed

  Priority application(s): 60/337,431 30.11.01 US; 60/405,652 22.08.02 US

21 August 2003 Application Open to Public Inspection

  Published as AU-A-2002365312

1 June 2006 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002365313-Inhibitors of factor XA and other serine proteases involved in the coagulation cascade

2002365311-BRANCHED CHAIN AMINO ACIDDEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES